GIMS gets ICMR nod for 5 research topics | Noida News
The hospital will conduct researches on multisystem inflammatory syndrome (MIS-C) among children, genome sequencing to identify variants of the virus in those who died of Covid, psychological stress differences between male and female healthcare workers during the pandemic, risks of post-Covid syndrome in western UP and tumours and lung cancers as a result of the virus.
These five studies will be conducted by four doctors of the institute — Dr Vivek Gupta associate professor in the department of pathology, Dr Rakesh Gupta, the GIMS director, Dr Bharti Bhandari Rathore, associate professor, and Dr Rambha Pathak.
A total of 10-12 research topics had been proposed to the ICMR in June. But the approval came only for five of them on July 23. The studies will be conducted on sample sizes ranging from less than 60 to more than 100 and may need one and a half years to complete.
“We had applied for 10-12 research projects to the ICMR on June 30. Five of the studies were shortlisted and approved by the research centre on July 23. These will be funded by the ICMR. For the others, we will have to wait for approval,” said Dr Gupta.
The research subjects awaiting approval include the effect of the second wave, both doses of the Covid vaccine on people and whether a booster dose is needed. GIMS had also proposed a study on mucormycosis in Covid patients and the relation between the two infections, the impact of the Covid vaccine on pregnant and lactating women and those who have reached menopause, vaccine hesitancy in rural people and the efficacy and safety of cross vaccination.
The Greater Noida hospital is already engaged in nine research projects related to Covid. Some of them are the phase 2 efficacy and safety of convalescent plasma in treatment of Covid, the mental and social health of healthcare personnel involved in pandemic management, evaluation of rapid antigen test protocols and biomarker identification in Covid. “Some of these studies are nearing completion while we are going ahead with the others,” said Dr Saurabh Srivastava, the chief medical superintendent at GIMS.